GlassScriptPhysician profile
Jon R Pritchett
NPI 1275554867
$2,457.58
in general payments reported to CMS, 2019-2025
28 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $360 · 2021: $234 · 2022: $265 · 2023: $398 · 2024: $304 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $312.88 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $295.40 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $223.66 | 2019-2025 | |
| Lilly USA, LLC | $208.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.81 | 2021-2025 | Jardiance, Ofev |
| Neurocrine Biosciences, INC. | $136.92 | 2022-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $123.27 | 2022-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $116.99 | 2025 | Diamondback Peripheral |
| Exact Sciences Corporation | $106.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $83.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $82.47 | 2021-2025 | Breztri, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $76.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.51 | 2019 | |
| Abbvie INC. | $64.37 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.49 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $31.58 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $29.53 | 2021 | |
| Merck Sharp & Dohme LLC | $24.61 | 2024 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.95 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $21.09 | 2021 | |
| Acadia Pharmaceuticals INC | $19.98 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.86 | 2025 | |
| Sumitomo Pharma America, INC. | $18.08 | 2025 | Gemtesa |
| Eisai INC. | $13.68 | 2020 | |
| Alfasigma USA, INC. | $12.97 | 2021 | |
| Medtronic Vascular, INC. | $12.48 | 2020 | |
| Amarin Pharma, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Pritchett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.